A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
Clinical trial NCT06566742 · RECRUITING
Trial details
- NCT number
- NCT06566742
- Sponsor
- M.D. Anderson Cancer Center
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-12-10
- Primary completion
- 2027-08-31
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.